Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)
ID: 346550Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/346550

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-130.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R01 Clinical Trial Optional)" aimed at advancing precision medicine for pregnant individuals, lactating persons, and children. This initiative seeks to support translational and clinical research that enhances understanding of drug actions, develops novel therapeutics, and improves the safety and efficacy of medications for these populations. The funding opportunity encourages interdisciplinary collaboration and innovative research approaches, including drug delivery systems and the integration of artificial intelligence in pediatric medicine. Interested applicants can find more details and submit proposals electronically via Grants.gov by May 7, 2026, with inquiries directed to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-130-Full-Announcement.html
    PAR-23-130.html
    The Department of Health and Human Services has issued a Notice of Funding Opportunity (NOFO) intended to promote translational research in maternal and pediatric pharmacology and therapeutics. This initiative, supported by various NIH institutes including NICHD, NIAID, NIDA, and NIMH, aims to develop innovative tools and therapies to enhance precision medicine for pregnant and lactating individuals, as well as children. Key goals include improving understanding of drug actions, addressing metabolic changes during pregnancy, and discovering safer medications. The funding opportunity encourages research on drug delivery systems, pharmacokinetic models, and the integration of artificial intelligence in pediatric medicine. Applications are welcomed from diverse organizations, emphasizing interdisciplinary collaboration and alignment with previous federal mandates like the Best Pharmaceuticals for Children Act. The application process requires adherence to specific guidelines, and proposals should be submitted electronically via Grants.gov by set deadlines. The funding is contingent upon the quality of applications and available resources, with maximum project durations of five years. This NOFO reflects a governmental priority to address significant gaps in maternal and pediatric therapeutics research, promoting safer healthcare outcomes for these populations.
    Similar Opportunities
    Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)" aimed at advancing research in drug safety and effectiveness for pregnant individuals, lactating persons, and children. This initiative seeks to support innovative projects that develop novel methodologies, enhance understanding of drug mechanisms, and promote precision medicine to address significant unmet medical needs in maternal and pediatric health. Eligible applicants include a wide range of institutions, such as historically black colleges and universities, tribal colleges, and various nonprofit organizations, with funding available up to $275,000 over a two-year period. Interested parties should note that applications are accepted until December 16, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity (PAR-23-037) aimed at promoting multisite clinical trials and observational studies focused on women, children, pregnant and lactating individuals, and persons with disabilities. The initiative seeks to enhance the rigor and reproducibility of clinical trial protocols, facilitate data sharing, and increase the involvement of diverse populations in research through the utilization of NICHD-supported Network infrastructure. This funding opportunity supports projects for up to five years, with budgets reflecting actual needs, and requires a rigorous pre-application process starting with a Letter of Inquiry. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with ongoing application cycles and a close date set for May 7, 2026.
    Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)" aimed at supporting innovative research into the mechanisms underlying structural birth defects. This grant encourages applicants to utilize animal models alongside human translational and clinical approaches, focusing on genetic, epigenetic, and environmental factors that contribute to these conditions. With over 120,000 infants affected annually in the U.S., this research is critical for public health, and projects may receive funding of up to $499,999 per year for a maximum of five years. Interested applicants must submit their proposals by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for more details at https://grants.nih.gov/grants/guide/pa-files/PAR-22-215.html.
    Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional)" aimed at investigating the interactions between HIV, antiretroviral therapy (ART), and substance use during pregnancy. This initiative seeks to enhance understanding of placental health and its implications for maternal and fetal outcomes, particularly focusing on the pathophysiology of placental abnormalities in the context of substance misuse. The NIH plans to allocate up to $2 million for fiscal year 2025 to support 2-5 research project grants, with applications opening on October 15, 2024, and a submission deadline of November 15, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for research titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at developing novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening. This initiative encourages diverse scientific research focused on improving screening technologies, therapeutic interventions, and preclinical testing, particularly for "high priority" genetic conditions that are not currently recommended for screening but could benefit from early identification and treatment. Eligible applicants include a wide range of organizations, such as educational institutions, community-based organizations, and tribal governments, with applications due by November 5, 2024. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-21-353.html.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for innovative research aimed at developing screening approaches and therapies for screenable disorders in newborns, designated as R21 - Clinical Trial Optional. This initiative encourages projects that focus on creating novel screening techniques and therapeutic interventions for potentially fatal or disabling conditions identified through newborn screening, particularly emphasizing early diagnosis and treatment to improve health outcomes. The program is part of NIH's commitment to advancing public health and reducing health disparities, with a funding ceiling of $275,000 available over a two-year period. Interested applicants, including a diverse range of institutions and organizations, must submit their proposals by November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R03 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns," aimed at encouraging research into novel screening methods and therapeutic interventions for serious genetic and congenital conditions identified through newborn screening. This initiative, under the R03 Small Grant Program, supports small-scale projects lasting up to two years with a budget of up to $50,000 per year, focusing on developing robust screening technologies to enhance early detection and treatment of disorders, thereby minimizing long-term health consequences. The program is particularly important for addressing high-priority conditions where screening is not currently recommended, and it emphasizes inclusivity in research by inviting applications from a diverse range of organizations, including higher education institutions and community-based organizations. Interested applicants should note that the application deadline is November 16, 2024, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Understanding the Impact of Healthcare System and Clinician Factors on Disparities in Maternal Morbidity and Mortality" (NOFO PAR-24-059). This initiative aims to support multidisciplinary research focused on addressing the high rates of maternal morbidity and mortality in the United States, particularly among racial and ethnic minorities, socioeconomically disadvantaged groups, and underserved rural populations. The program encourages innovative intervention studies that evaluate healthcare factors affecting maternal health, with the goal of reducing disparities and improving outcomes across the continuum of care from prenatal to postpartum. Eligible applicants include a range of organizations, and awards can last up to five years, with budgets tailored to project needs. Interested parties can find more information and apply by visiting the NIH grants website, with the application deadline set for January 7, 2027.
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)" aimed at advancing innovative research into precision probiotic interventions. This initiative seeks applications that will investigate person-specific factors influencing probiotic responses, such as microbiome composition, age, sex, genetic background, and lifestyle, to identify subgroups that may benefit from tailored probiotic treatments. The funding is crucial for addressing variability in human responses to probiotics and aims to enhance health outcomes through targeted interventions. Applicants can request up to $350,000 per year for a maximum of four years, with the application deadline set for June 2, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-239.html.
    Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Methods for Safe, Noninvasive, Real Time Assessment of Placenta Development and Function Across Pregnancy" under the R01 grant mechanism, which does not allow clinical trials. This initiative aims to support the development and clinical validation of innovative, non-invasive methods to assess placental health throughout pregnancy, addressing critical issues such as preeclampsia and stillbirth. The funding is part of the Human Placenta Project and encourages applications from a diverse range of organizations, including educational institutions and community-based organizations, with no budget limits specified, although proposals should reflect actual project needs. Interested applicants must submit their proposals by November 5, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.